Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Thomas
05.06.25
Pillsbury advised Biolinq Incorporated, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, in raising $100 million in Series C funding.
Alpha Wave Ventures led the funding round, with additional participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital.
As reported by a press release, the funding is expected to support Biolinq through the U.S. regulatory approval process as the company prepares to bring the first autonomous intradermal glucose sensor to market.
Click here to learn more about the transaction.
The Pillsbury deal team was led by Corporate partner Mike Hird and associate Kit Ryan and included International Trade partner Matthew Rabinowitz, Emerging Companies & Venture Capital counsel Walter Scott and senior legal analyst Rory O’Neill.